

Communication

Enzyme-Free Plasmonic Biosensor for Direct Detection of Neurotransmitter Dopamine from Whole Blood

Abraham Vázquez-Guardado, Swetha Barkam, Madison Peppler, Aritra Biswas, Wessley Dennis, Soumen Das, Sudipta Seal, and Debashis Chanda

Nano Lett., **Just Accepted Manuscript** • DOI: 10.1021/acs.nanolett.8b04253 • Publication Date (Web): 11 Dec 2018

Downloaded from <http://pubs.acs.org> on December 13, 2018

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications

is published by the American Chemical Society, 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Enzyme-Free Plasmonic Biosensor for Direct Detection of Neurotransmitter Dopamine from Whole Blood

Abraham Vázquez-Guardado,^{1,2} Swetha Barkam,³ Madison Peppler,³ Aritra Biswas,^{1,2} Wessley Dennis,² Soumen Das,³ Sudipta Seal,^{2,3,4} and Debashis Chanda^{1,2,6,*}

¹CREOL, College of Optics and Photonics, University of Central Florida, Orlando, Florida 32816, USA

²NanoScience Technology Center, University of Central Florida, Orlando, Florida 32826, USA

³Advanced Materials Processing and Analysis Center, University of Central Florida, Orlando, Florida 32816, USA

⁴College of Medicine, University of Central Florida, Orlando, Florida 32816, USA

⁵Materials Science and Engineering, University of Central Florida, Orlando, Florida 32816, USA

⁶Department of Physics, University of Central Florida, Orlando, Florida 32816, USA

*Corresponding author: debashis.chanda@ucf.edu; phone number +1 407 823 4575

Abstract

Complex biological fluids without pre-treatment, separation or purification, impose stringent limitations on the practical deployment of label-free plasmonic biosensors for advanced assays needed in point of care applications. In this work, we present an enzyme-free plasmonic neurotransmitter dopamine biosensor integrated with a microfluidic plasma separator. This integrated device allows the in-line separation of plasma directly from the blood stream and channels it to the active detection area, where inorganic cerium oxide nanoparticles function as local selective dopamine binding sites through strong surface redox reaction. A thorough understanding and engineering of the nanoparticles is carried out in order to maximize its dopamine sensitivity and selectivity. We obtain detection of dopamine at 100 fM concentration in simulated body fluid and 1 nM directly from blood without any prior sample preparation. The detection selectivity is found to be at least five times higher compared to the common interfering species. This demonstration shows the feasibility of the practical implementation of the proposed plasmonic system in detection of variety of biomarkers directly from the complex biological fluids.

Keywords: Plasmonic biosensor, dopamine sensing, whole blood plasma separator, cerium oxide nanoparticles, integrated plasmonic–microfluidic chip, point of care applications.

Main text

Dopamine (DA) is an organic electrochemical neurotransmitter of paramount importance for the proper functioning of the neural system. Many neurological processes are associated with the active dopaminergic neurotransmission, for example happiness, pleasure, cognition and fine motor control. DA dysfunction, on the other hand, underlies the pathogenesis of several neurological disorders such as Parkinson's disease, Huntington's disease, depression, schizophrenia or psychosis. In addition, it is also the biomarker for certain cancer strains such as pheochromocytoma¹⁻³, neuroblastoma⁴, or paraganglioma⁵⁻⁸. For example, the plasma DA concentration in healthy adults ranges in the 0.1 nM⁹ and those with head and neck paragangliomas ranges up to 6 nM¹⁰. Therefore, detecting physiological and

clinically relevant concentrations of DA with high sensitivity and selectivity is of great significance in basic pathophysiology research, drug development, as well as in disease diagnosis and management.

Conventional analytical methods for DA detection are the enzyme-linked immunosorbent assay (ELISA) or the high-performance liquid chromatography (HPLC) as the analyte separation method coupled with fluorometry, coulometry, electrochemical or mass spectroscopies as detection techniques¹¹⁻¹⁵. Apart from the challenges associated to selectivity, sample consumption and analysis times, these methods require rigorous sample preparation to achieve the desired specificity and sensitivity (detection limit/time of 1 nM/100 min for ELISA and 4 pM/60 min for HPLC). In addition to the assay's high costs, these techniques require specialized laboratory equipment that prevents their translation to point of care applications where the access to high-end equipment is limited. With the aim to circumvent these aforementioned limitations, a wide range of alternative detection schemes have been previously reported, ranging from electrochemical to optical sensors. In the case of electrochemical detection, surface-modified microelectrodes are typically employed to enhance its detection capability^{16,17}: for instance electrodes are modified with active sensing materials such as metal or dielectric nanoparticles¹⁸⁻²⁰ or conductive polymers^{21,22}. Electrochemical techniques have the advantages of low cost and rapid detection. However, there are limitations related to the intrinsic transduction mechanism, such as electro-polymerization leading to biofouling, rendering the device inactive. Another important concern is its reduced selectivity due to oxidizable DA metabolites and other compounds like ascorbic acid, which extensively interfere with the detection of DA as they have similar oxidizing potentials. Furthermore, the DA detection limits in buffer for most sensitive electrodes are around 1 to 0.1 nM^{16,17}. There is a report of 100 fM detection limit based on specialized field-effect-transistor design²¹. Optical DA sensors, on the other hand, are based on localized²³⁻²⁶ or propagating²⁷⁻²⁹ surface plasmon polariton (LSP and SPP, respectively), which are enzymatically functionalized to bind to DA. However, the main

1
2
3 limitation in DA detection is its low mass (153.18 Da) hence the lowest detection limits are still within 1
4 nM for most LSP and SPP and 200 fM for SPP with dedicated gold nanoparticle amplification
5 mechanism³⁰. Though, previous publications demonstrate optical or electrochemical DA detection in
6 buffer solutions¹⁷⁻²⁹ and off-line extracted serum/plasma^{16,19,31}, the direct detection from biological body
7 fluids, such as blood plasma, without sample preparation or purification still remains challenging and
8 unexplored.
9

10
11
12 In this work, we demonstrate an integrated enzyme-free DA biosensor comprised of an active
13 nanostructured plasmonic substrate (NPS) functionalized with oxygen-deficient cerium oxide
14 nanoparticles (CNP) and a passive plasma separator microfluidic chip. The inorganic redox active
15 CNP's surface acts as selective DA binding sites for the selective optical detection on the NPS³².
16 Traditional affinity layers for DA detection, for example those used in ELISA, employ antibodies or
17 cellular membrane receptors. Such biological entities require specialized storage, handling and
18 preparation in order to maintain their affinity, sensitivity and to avoid denaturation. In contrast,
19 inorganic CNP do not suffer from these constraints, which enhance the robustness, shelf life and reduce
20 the assay cost considerably. When coupled to the microfluidic system, the proposed device extracts
21 blood plasma directly from the inlet blood stream without additional sample preparation or purification
22 and allows optical readout on the CNP-coated NPS. In this initial demonstration the detection limits of
23 DA was measured 100 fM and 1 nM, in simulated body fluid and blood plasma, respectively.
24 Furthermore, the sensor's response was compared with common interfering species and it was found
25 that DA's response exceeds at least by 5.3 and 20 times for ascorbic acid and epinephrine, respectively.
26 No interference was observed for 3, 4-Dihydroxyphenylacetic acid (DOPAC).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Integrated enzyme-free dopamine sensing. (a) Schematic representation of the integrated device comprised of a plasmonic sensor coupled to a microfluidic chip containing the plasma separator module. (b) Top view and cross section SEM of one CNP-functionalized plasmonic substrate. (c) Experimental spectra of one fabricated device (red), its spectral response after CNP coating (green) and after DA incubation at one representative concentration (blue). Right panels represent graphically these three phenomenological events.

The integrated device incorporates three essential elements: the sensitive NPS^{32,33}, the selective CNP functionalizing the sensor's surface and the microfluidic plasma separator as shown in Fig. 1(a). The active NPS is formed by a gold hole-disk array coupled to an asymmetric photonic cavity fabricated using the nanoimprinting technique (see Supporting Information for more information), which proved to be robust and reliable in producing reproducible narrowband cavity-coupled plasmonic. This information is shown in Fig. S1, where the distribution of 930 spectral responses in 103 manually imprinted samples is summarized (mean plasmonic resonance at 823 nm with standard deviation of 16 nm). We believe an automated imprinting technique will further improve the sensor reproducibility. The NPS creates enhanced near-field via excitation of narrow linewidth hybrid cavity-coupled localized surface plasmonic resonance (LSPR), whose resonance location is determined by the hole/disk diameter and cavity thickness³²⁻³⁴. The LSPR is sensitive to minute perturbations in the optical density of the

surrounding environment induced by subwavelength inorganic film accumulation or organic biomolecules, bulk refractive index or isolated nanoparticles^{32,35}. Any of these possible interaction scenarios induce an accumulation of polarization charges on the substrate producing the LSPR to redshift non-selectively.

The surface selectivity is introduced by binding the complementary analyte surfactant to the active plasmonic surface –such as an antibody against the target antigen for selective binding. In this study, the NPS's surface is modified with CNP, which have strong affinity towards electroactive compounds such as DA^{36,37}. Figure 1(b) shows a scanning electron microscope image of a representative CNP coated plasmonic surface. Upon mutual redox activity DA binds on the CNP's surface inducing a change in the CNP effective refractive index^{36,38}. This effect is manifested in the LSPR response, which experiences a resonance shift proportional to the overall surface coverage. This mechanism is observed in Fig. 1(c) containing the reflectance spectra measured experimentally at three stages of the characterization process: bare plasmonic substrate, after CNP coating and after CNP+DA coating (see Supporting Information for more details). The overall sensor response is determined by the LSPR shift from CNP to the DA binding state; see Fig. 1(c).

The passive microfluidic plasma separator chip exploits a series of cascaded hydrodynamic and biophysical effects. In the first effect, the Zweifach-Fung bifurcation law, a microfluidic channel that bifurcates into two outlets with asymmetric flow rate ratio, at least 2.5:1, imposes a selective drag force on red and white blood cells (BCs) towards the path with higher-pressure^{39,40}. As a result the channel with large flow resistance carries the BCs-free plasma while the one with low flow resistance carries the residual media containing the large density of BCs towards the waste reservoir outlet. Such a separation method is further amplified by the fact that BCs migrate towards the center of the flow channel, or blood vessel in biological systems, with cross-sections less than 300 μm leaving a BCs-free layer on the walls.

Also known as the Fahraeus effect, its influence on BCs migration to the center increases as the channel contracts –a self-regulated effect exploited by the vascular system. Finally, inertial focusing permits BCs migration to the center due to the balance between lift and drag forces produced in channel bends ⁴¹⁻⁴³. Along with the Fahraeus effect the inertial focusing obtained by the contracting bent further enhances the plasma separation at the bifurcation (see Fig. S4). The device channels the separated plasma towards the active plasmonic biosensing area as observed in Fig. 1(a) where the spectroscopic optical interrogation takes place. The synergetic interaction among these elements enables efficient extraction of plasma from the complex biological fluids, such as blood.

At the nano scale (3-5 nm diameter) CNP support the coexistence of Ce^{3+} and Ce^{4+} oxidation states on its surface forming oxygen vacancies in the crystal lattice^{36,44-46}. These oxygen vacancies act like catalytic hotspots that induce unique redox reactions with electroactive compounds, such as serotonin, epinephrine, DA and norepinephrine³⁶. Previous studies showed that due to the redox reaction CNP interaction with DA form charge complexes, thereby oxidizing dopamine³⁶. This results in dopaquinone-CNP hybrid complexes with an intermediate semiquinone state observed as a red shift in the characteristic UV-visible spectra. The ratio $\text{Ce}^{3+}/\text{Ce}^{4+}$ on the surface (CeSR) of CNP is the metrics for CNP redox activity, which regulates its enhanced catalytic property and controls the extent of reaction with different electrochemical compounds, *i.e.* DA. In order to understand the CeSR effect toward DA interaction, two relatively different CNP compositions were prepared that exhibit different surface chemistry: CNP1 with $\text{CeSR} > 1$ and CNP2 with $\text{CeSR} < 1$ (see Supporting Information for more details). These two particles were carefully formulated to have similar spherical shape and size with diameter of 3-5 nm that differ only in their surface chemistry, see Fig. S2(a). The X-ray photoelectron spectroscopy (XPS) characterization shows that CNP1 has a CeSR of 2.57 and CNP2 has that of 0.68 as seen Fig. S2(b). The DA-CNP interaction is studied using in-situ UV-visible spectro-




Figure 2. CNP-dopamine interaction analysis in-situ. (a) Dopamine UV-visible spectro-electrochemical analysis as a function of external potential: 0, 0.1, 0.5 and 0.8 V. (b) Optical images of dopamine and its interaction with CNP1 (CeSR > 1) and CNP2 (CeSR < 1). UV-visible spectro-electrochemical analysis of pristine (top) and mixed with dopamine (bottom) for CNP1 (c) and CNP2 (d) as a function of oxidizing potential: 0, 0.1, 0.5 and 0.8 V.

electrochemistry analysis on both of these CeSR compositions (see Supporting Information for more details). This study helps to gauge the change in surface chemistry of CNP in the presence of dopamine by oxidizing the solution using an external potential applied to the CNP-DA solution.

Dopamine has two distinct absorption peaks corresponding to two oxidation states. In pristine un-oxidized DA an absorption peak at 281 nm dominates the UV-visible spectrum. An increasing external potential (0-0.8 V) oxidizes DA and a second absorption peak starts appearing at 390 nm while the peak at 281 nm diminishes simultaneously, as observed in Fig. 2(a). Moreover, CNP1 (CeSR > 1; more Ce⁴⁺ on the surface) solution has a Ce⁴⁺ extinction peak at 290 nm. Upon oxidation its Ce⁴⁺ surface concentration further increases indicated by the increase in the peak height of the 290 nm extinction peak in Fig. 2(c). On the other hand, CNP2 (CeSR < 1; more Ce³⁺ on the surface) solution has a distinctive Ce³⁺ peak at 253 nm with negligible Ce⁴⁺ extinction peak. Upon oxidation, the increase in

Ce⁴⁺ concentration is manifested as a baseline upshift resulting in the formation of Ce⁺⁴ as observed in Fig. 2(d). Now, when CNP1 interacts with DA the free un-oxidized state population decreases (drop of extinction peak at 281 nm), whereas the absorption intensity of Ce⁴⁺ peak remains unchanged as observed in Fig. 2(c). It is important to notice that the absence of free oxidized DA, whose extinction peak does not strongly show at 390 nm, suggests its absorption onto the CNP surface, which indicates a strong interaction between CNP1 and DA. However, when CNP2 interacts with DA, the spectra indicate a superposition of oxidized CNP2 (observed by the increase in the Ce⁴⁺ at 290 nm) and DA (population inversion as in Fig 2(a)) individually. Such a behavior indicates hardly any interaction upon increasing the oxidation potential as shown in Fig. 2(d). In other words, the oxidation behavior of CNP2 and dopamine are mutually independent of each other.

In addition, the DA-CNP complex formation was visually observed. Initially both CNP formulations and DA appear clear. Once mixed, there is an immediate change in color for CNP1+DA (dark brownish see Fig. 2(b)) compared to hardly any change observed in CNP2+DA as shown in Fig. 2(b). This suggests the rapid formation of charge transfer complex, in the form of nanoparticle coating, with a decrease of free un-oxidized DA. As previously suggested the oxidation of dopamine by CNP leads to formation of reactive dopaquinone intermediates, which bind to the surface of CNP. This distinctly suggests that the oxidation followed by the binding on surface of CNP leads to a decline of free DA concentration thereby indicating the preference of DA oxidation for CNP with $CeSR > 1^{36}$. The CNP (from here on refereeing to CNP1) affinity towards DA is exploited as an enzyme-free DA inorganic ligand in this on-chip biosensing demonstration.

The first characterization is to validate the DA detection capability on this CNP-functionalized NPS. NPS were coated with polyvinyl alcohol (PVA) stabilized CNP. In order to improve uniformity and area coverage, denser CNP layer is used which in turn improved the sensor reproducibility and




Figure 3. Characterization in aqueous solution. (a) Dopamine sensing characterization in SBF from 100 fM to 100 nM. Control experiments represent the sensors response in the absence of CNP coating and buffer effect. Inset represents the characterization flowchart. The shaded area represents the baseline of the sensor. (b) Interfering species response test: DOPAC, ascorbic acid, epinephrine and dopamine at 100 nM in SBF. (c) Dopamine sensing feasibility test in sheep plasma. Control experiments represent the sensors response in the absence of CNP coating and buffer (plasma) effect. Error bars represent the standard deviation from the mean (n=9).

sensitivity. The optimization was done using different PVA:CNP solution ratio and spin coating cycles producing different surface coverage as observed in Fig. S3(a), followed by 100 nM DA incubation (see Supporting Information for more details). It was observed that the denser the surface coverage due to additional coating cycles the larger the spectral shift; however, considerable CNP agglomeration accompanies this process as well. Such an effect hinders the sensitivity of the device due to the decline in oxidizability efficiency produced by the lower surface area of agglomerated CNP observed in the sensor's response as plotted in Fig. S3(b). Considering this trade-off eight coating cycles was found to be optimum.

Upon surface functionalization optimization the sensor's response was characterized. DA at various concentrations was incubated in simulated body fluid (SBF) –a buffer whose ion concentration is close to that of human blood plasma, as well as different control samples and plotted in Fig. 3(a); (see

Supporting Information for more details). DA in SBF with concentration between 100 fM to 100 nM produced a plasmonic shift according to its concentration and follows a standard sigmoid response fitted curve ($R^2 = 0.98$) in Fig. 3(a). The estimated limit of detection is 45 fM determined when the standard sigmoid curve falls to 10% of its maximum (EC10), which is an order of magnitude smaller than that of previous SP-based DA sensing using plasmonic nanoparticles as signal amplification³⁰. In addition three control measurements were carried out: SBF incubation on an uncoated sensor, CNP coated sensor and just PVA coated sensor. All these responses produced a residual response introduced by the combination of the sensor substrates and its functionalizing constituents in the absence of DA, which fall below the detection limit. Such a residual response of $\Delta\lambda \sim 1.48$ nm observed in the shaded area in Fig. 3(a) is the baseline of the device, which works as the reference to account positive response from the sensor. Then, the sensor's response was tested against common DA interfering species, such as DOPAC, ascorbic acid, and epinephrine. It is clear that CNP's response to DOPAC is negligible as observed in Fig. 3(b), while it is at least 5.3 and 20 times larger than ascorbic acid and epinephrine, respectively, which indicates its selectivity toward DA.

Next, DA detection feasibility in a more complex matrix, such as blood plasma, was tested. Two concentrations of DA, 10 and 100 nM, were spiked in purchased sheep plasma and then incubated on the sensors (see Supporting Information for more details). In this particular situation, plasma which is comprised of a wide range of proteins, undergoes electrostatic surface binding on the sensor's surface. This undesirable effect introduces a larger background as observed in the plasmonic shift in Fig. 3(c) in presence and absence of DA, compared to those in Fig. 3(a) and Fig. 3(b). Nevertheless, the sensor produced two distinguishable signals in response to the DA. These characterizations demonstrate the enzyme-free detection of DA in buffers, such as SBF, as well as in complex biological fluids, such as blood plasma.




Figure 4. Dopamine detection from whole blood. (a) Microfluidic chip containing the in-line plasma separation. Colored channels are represented with colored solutions for illustration purposes. Bottom panel shows plasma separation demonstration on one device tested with *HCT* 22.3% flowing at ~ 0.1 ml/min. (b) DA detection directly from in-line separated plasma for four samples, 100 nM, 10 nM, 1 nM and control (without DA) in whole blood with *HCT* 22.3%. Four events are observed: stabilization in buffer, plasma separation, plasma incubation and flush. (c) Sensor's response for DA detection in whole blood through the integrated plasma separator chip for three samples at 100 nM, 10 nM and 1 nM and a control. Error bars indicate the sensorgrams standard deviation from the mean.

The final demonstration corresponds to the direct detection of DA in plasma obtained from whole blood. The integrated device incorporates a microfluidic module that performs in-line blood plasma separation as shown in Fig. 1(a). The microfluidic channel footprint, adapted from previous reports^{39,47}, is shown in Fig. S4. This module extracts a portion of the blood plasma and directs it towards the active CNP coated NPS. The microfluidic chip is laminated on a previously fabricated and CNP functionalized plasmonic substrate and held together with the help of an acrylic clamp as observed in Fig. S5. Two inlets provide access of phosphate-buffered saline (PBS) buffer and whole blood into the chip. The external fluid distribution configuration is drawn in Fig. S6. In first instance the PBS solution is flown into the channel at ~ 0.02 ml/min to stabilize the sensor, producing a baseline ($\Delta\lambda_0$) response. Next the blood flow is introduced at ~ 0.1 ml/min to produce plasma separation, as seen in Fig.

4(a)-bottom panel. This high-speed plasma solution is flown for approximately one to two minutes until full plasma separation occurs. Then, the flow is stopped in order to allow further interaction between the freestanding DA in the separated plasma solution and the CNP attached to the sensor's surface. During the plasma separation and incubation steps proteins bind to the surface as observed in Fig. 3(c) and Fig. 4(b) resulting in the inherent sensor baseline response after the flushing step. At the same time DA is captured on the CNP surface proportional to the total free DA in the solution producing a total sensor response of $\Delta\lambda_2$. The total sensor response at this state will correspond to $\Delta\lambda_2 - \Delta\lambda_0$. Finally, the plasma is flushed with PBS cleaning the proteins from the sensor surface. However, residual protein electrostatically attached to the surface produces background spectral shift ($\Delta\lambda_1$). The sensor response towards DA is then estimated as the total response minus the final background: $(\Delta\lambda_2 - \lambda_0) - \Delta\lambda_1$. Figure 4(b) shows the LSPR time evolution during the assay in the integrated device for three DA concentrations, 100 nM, 10 nM and 1 nM along with one control sample without DA. The combined sensor response for these four samples is plotted in Fig. 4(c), which indicates detection of DA in the range of 1 nM. This initial detection range typically benefit in the detection of DA in dopamine-secreting paragangliomas tumors whose typical levels are from 1 to 363 nM concentrations⁸. Standard analytical methods for DA detection, see Table S1, reach low detection limits or selectivity at the tradeoff between long assay times and laborious sample preparations protocols. In contrast to other detection techniques like ELISA or HPLC where extensive sample preparation is required, the proposed method preforms detection directly from whole blood. The preliminary 1 nM detection limit and 5 minutes detection time from whole blood are comparable and well within the standard norms. These systematic measurements show that with additional design optimization the detection limit can be further reduced. Moreover, this principle can be straightforwardly extrapolated for the direct detection of various biomarkers directly from blood even in presence of various interfering species.

1
2
3 In this work, we presented for the first time the demonstration of DA detection from a complex
4 biological fluid using an enzyme-free DA plasmonic biosensor integrated with a dynamic blood plasma
5 separator chip. The relevance of this work not only relies on the enzyme-free selective detection of DA
6 in the plasmonic sensor but the successful detection from a complex matrix such as whole blood without
7 sample preparation in an integrated microfluidic device. This concept opens up the opportunity for more
8 complex label-free assays to be developed to target potential antigen and biomarkers in raw biological
9 fluids using sensitive plasmonic substrates. However, performing the detection of DA, as well as other
10 antigen or biomarkers, in plasma extracted from whole blood without preparation or purification, is
11 susceptible to inherent protein fouling due to the high protein content in biological fluids and hence
12 further work is still needed to establish a generalized detection protocol. Overall, the proposed label-free
13 plasmonic biosensors have proved its potential in low concentration detection of biomarkers based on a
14 low cost integrated platform.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supporting Information.

The accompanying supporting information contains cerium oxide nanoparticles synthesis and characterization, device fabrication, optical characterization, microfluidic chip fabrication and specifications, fluid sample preparations, supporting figures and tables.

Author contributions

A.V.G and D.C. conceived the idea. A.V.G., S.D. and S.B. designed the experiments. A.V.G., S.B., M.P. and A.B. performed the experiments. A.V.G. and W.D. developed the Labview interface. A.V.G. analyzed the data. A.V.G. and D.C. co-wrote the manuscript. S.B. and S.S. edited the manuscript. S.S. and D.C. contributed with materials/analysis tools.

Competing interests: The authors declare no competing financial interests.

Acknowledgements


This work was supported by the National Science Foundation under grant ECCS/EPMD-1808045 and Northrop Grumman University Research Program. A.V.G. acknowledges support from the Consejo Nacional de Ciencia y Tecnologia (CONACyT).

References.

- (1) Dubois, L. A.; Gray, D. K. *World J. Surg.* **2005**, 29 (7), 909–913.
- (2) Tippet, P. A.; McEwan, A. J.; Ackery, D. M. *Clin Endocrinol* **1986**, 25 (4), 401–410.
- (3) Januszewicz, W.; Wocial, B.; Januszewicz, A.; Gryglas, P.; Prejbisz, A. *Blood Press.* **2001**, 10 (4), 212–216.
- (4) Anagnoste, B.; Freedman, L. S.; Goldstein, M.; Broome, J.; Fuxe, K. *Proc. Natl. Acad. Sci. USA* **1972**, 69 (7), 1883–1886.
- (5) Van Der Horst-Schrivers, A. N. A.; Osinga, T. E.; Kema, I. P.; Van Der Laan, B. F. A. M.; Dullaart, R. P. F. *Anticancer Res.* **2010**, 30 (12), 5153–5158.
- (6) Soh, A. W. E.; Kek, P. C. *Intern. Med.* **2012**, 51 (6), 613–618.
- (7) Yi, J. W.; Oh, E. M.; Lee, K. E.; Choi, J. Y.; Koo, D. H.; Kim, K. J.; Jung, K.-C.; Kim, S.-Y.; Youn, Y.-K. *J Korean Surg Soc* **2012**, 82 (6), 389–393.
- (8) Eisenhofer, G.; Goldstein, D. S.; Sullivan, P.; Csako, G.; Brouwers, F. M.; Lai, E. W.; Adams, K. T.; Pacak, K. *J Clin Endocrinol Metab* **2005**, 90 (4), 2068–2075.

- (9) Goldstein, D. S.; Eisenhofer, G.; Kopin, I. J. *J Pharmacol Exp Ther* **2003**, *305* (3), 800–811.
- (10) Van Der Horst-Schrivers, A. N. A.; Osinga, T. E.; Kema, I. P.; Van Der Laan, B. F. A. M.; Dullaart, R. P. F. *Anticancer Res.* **2010**, *30* (12), 5153–5158.
- (11) Hubbard, K. E.; Wells, A.; Owens, T. S.; Tagen, M.; Fraga, C. H.; Stewart, C. F. *Biomed. Chromatogr.* **2010**, *24* (6), 626–631.
- (12) Raggi, M. A.; Sabbioni, C.; Nicoletta, G.; Mandrioli, R.; Gerra, G. *J. Sep. Science* **2003**, *26* (12–13), 1141–1146.
- (13) Kim, J.; Jeon, M.; Paeng, K.-J.; Paeng, I. R. *Anal. Chim. Acta.* **2008**, *619* (1), 87–93.
- (14) Yoshitake, T.; Yoshitake, S.; Fujino, K.; Nohta, H.; Yamaguchi, M.; Kehr, J. *Journal of Neuroscience Methods* **2004**, *140* (1–2), 163–168.
- (15) Hows, M. E. P.; Lacroix, L.; Heidbreder, C.; Organ, A. J.; Shah, A. J. *Journal of Neuroscience Methods* **2004**, *138* (1–2), 123–132.
- (16) Wang, Y.; Zhang, Y.; Hou, C.; Liu, M. *RSC Advances* **2015**, *5*, 98260–98268.
- (17) Feng, X.; Zhang, Y.; Zhou, J.; Li, Y.; Chen, S.; Zhang, L.; Ma, Y.; Wang, L.; Yan, X. *Nanoscale* **2015**, *7* (6), 2427–2432.
- (18) Baron, R.; Zayats, M.; Willner, I. *Anal. Chem.* **2005**, *77* (6), 1566–1571.
- (19) Liu, K.; Pang, H.; Zhang, J.; Huang, H.; Liu, Q.; Chu, Y. *RSC Advances* **2014**, *4* (17), 8415–8420.
- (20) Lin, Y.; Chen, C.; Wang, C.; Pu, F.; Ren, J.; Qu, X. *Chem. Commun. (Camb.)* **2011**, *47* (4), 1181–1183.
- (21) Lee, J. S.; Oh, J.; Kim, S. G.; Jang, J. *Small* **2015**, *11* (20), 2399–2406.
- (22) Zhong, M.; Teng, Y.; Pang, S.; Yan, L.; Kan, X. *Biosens. Bioelectron.* **2015**, *64* (c), 212–218.
- (23) Raj, D. R.; Prasanth, S.; Vineeshkumar, T. V.; Sudarsanakumar, C. *Sensor Actuat. B: Chem.* **2015**, *224*, 600–606.
- (24) Choi, J.-H.; Lee, J.-H.; Oh, B.-K.; Choi, J.-W. *J Nanosci Nanotechnol* **2014**, *14* (8), 5658–5661.
- (25) Choi, Y.; Choi, J.-H.; Liu, L.; Oh, B.-K.; Park, S. *Chem. Mater.* **2013**, *25* (6), 919–926.
- (26) Biswal, J.; Misra, N.; Borde, L. C.; Sabharwal, S. *Radiation Physics and Chemistry* **2013**, *83*, 67–73.
- (27) Sebők, D.; Csapó, E.; Preočanin, T.; Bohus, G.; Kallay, N.; Dékány, I. *Croat. Chem. Acta* **2013**, *86* (3), 287–295.
- (28) Kumbhat, S.; Shankaran, D. R.; Kim, S. J.; Gobi, K. V.; Joshi, V.; Miura, N. *Chem Lett* **2006**, *35* (6), 678–679.
- (29) Matsui, J.; Akamatsu, K.; Hara, N.; Miyoshi, D.; Nawafune, H.; Tamaki, K.; Sugimoto, N. *Anal. Chem.* **2005**, *77* (13), 4282–4285.
- (30) Cao, Y.; McDermott, M. T. *bioRxiv* **2018**, 1–24.
- (31) Yadav, S. K.; Rosy, Oyama, M.; Goyal, R. N. *J. Electrochem. Soc.* **2013**, *161* (1), H41–H46.
- (32) Vázquez-Guardado, A.; Smith, A.; Wilson, W.; Ortega, J.; Perez, J. M.; Chanda, D. *Opt. Express* **2016**, *24* (22), 25785–12.
- (33) Chanda, D.; Shigeta, K.; Truong, T.; Lui, E.; Mihi, A.; Schulmerich, M.; Braun, P. V.; Bhargava, R.; Rogers, J. A. *Nat. Commun.* **2011**, *2*, 479–7.
- (34) Vázquez-Guardado, A.; Safaei, A.; Modak, S.; Franklin, D.; Chanda, D. *Phys. Rev. Lett.* **2014**, *113* (26), 263902.
- (35) Li, J.; Ye, J.; Chen, C.; Li, Y.; Verellen, N.; Moshchalkov, V. V.; Lagae, L.; Van Dorpe, P. *ACS Photonics* **2015**, *2* (3), 425–431.
- (36) Hayat, A.; Andreescu, D.; Bulbul, G.; Andreescu, S. *Journal of Colloid And Interface Science* **2014**, *418* (C), 240–245.

- (37) Bulbul, G.; Hayat, A.; Liu, X.; Andreescu, S. *RSC Advances* **2016**, *6*, 60007–60014.
- (38) Ghosh Chaudhuri, R.; Paria, S. *Chem. Rev.* **2012**, *112* (4), 2373–2433.
- (39) Tripathi, S.; Kumar, Y. V. B.; Agrawal, A.; Prabhakar, A.; Joshi, S. S. *Sci. Rep.* **2016**, *6*, 26749.
- (40) Yang, S.; Ündar, A.; Zahn, J. D. *Lab Chip* **2006**, *6* (7), 871–880.
- (41) Martel, J. M.; Toner, M. *Sci. Rep.* **2013**, *3* (1), 209–8.
- (42) Di Carlo, D.; Edd, J. F.; Irimia, D.; Tompkins, R. G.; Toner, M. *Anal. Chem.* **2008**, *80* (6), 2204–2211.
- (43) Seo, J.; Lean, M. H.; Kole, A. *Appl. Phys. Lett.* **2007**, *91* (3), 033901–033904.
- (44) Reed, K.; Cormack, A.; Kulkarni, A.; Mayton, M.; Sayle, D.; Klaessig, F.; Stadler, B. *Environmental Science: Nano* **2014**, *1*, 390–405.
- (45) Karakoti, A. S.; Monteiro-Riviere, N. A.; Aggarwal, R.; Davis, J. P.; Narayan, R. J.; Self, W. T.; McGinnis, J.; Seal, S. *JOM (1989)* **2008**, *60* (3), 33–37.
- (46) Das, S.; Dowding, J. M.; Klump, K. E.; McGinnis, J. F.; Self, W.; Seal, S. *Nanomedicine* **2013**, *8* (9), 1483–1508.
- (47) Prabhakar, A.; Kumar, Y. V. B. V.; Tripathi, S.; Agrawal, A. *Microfluidics and Nanofluidics* **2015**, *18*, 995–1006.



For TOC only

72x35mm (300 x 300 DPI)